Exelixis Management

Management criteria checks 4/4

Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 14.33 years. total yearly compensation is $16.42M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $53.17M. The average tenure of the management team and the board of directors is 8.5 years and 7.4 years respectively.

Key information

Mike Morrissey

Chief executive officer

US$16.4m

Total compensation

CEO salary percentage7.3%
CEO tenure14.3yrs
CEO ownership0.5%
Management average tenure8.5yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

CEO Compensation Analysis

How has Mike Morrissey's remuneration changed compared to Exelixis's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$467m

Jun 30 2024n/an/a

US$350m

Mar 31 2024n/an/a

US$205m

Dec 31 2023n/an/a

US$208m

Sep 30 2023n/an/a

US$92m

Jun 30 2023n/an/a

US$164m

Mar 31 2023n/an/a

US$154m

Dec 31 2022US$17mUS$1m

US$182m

Sep 30 2022n/an/a

US$308m

Jun 30 2022n/an/a

US$273m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$8mUS$1m

US$231m

Sep 30 2021n/an/a

US$164m

Jun 30 2021n/an/a

US$94m

Mar 31 2021n/an/a

US$65m

Dec 31 2020n/an/a

US$112m

Sep 30 2020n/an/a

US$152m

Jun 30 2020n/an/a

US$282m

Mar 31 2020n/an/a

US$294m

Dec 31 2019n/an/a

US$321m

Sep 30 2019n/an/a

US$612m

Jun 30 2019n/an/a

US$642m

Mar 31 2019n/an/a

US$650m

Dec 31 2018n/an/a

US$690m

Sep 30 2018n/an/a

US$368m

Jun 30 2018n/an/a

US$323m

Mar 31 2018n/an/a

US$253m

Dec 31 2017n/an/a

US$154m

Compensation vs Market: Mike's total compensation ($USD16.42M) is about average for companies of similar size in the US market ($USD12.87M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


CEO

Mike Morrissey (63 yo)

14.3yrs

Tenure

US$16,423,307

Compensation

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...


Leadership Team

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 42.3m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.55%
$ 53.2m
Christopher Senner
Executive VP & CFO9.3yrsUS$4.95m0.16%
$ 15.4m
Dana Aftab
Executive VP of Discovery and Translational Research & Chief Scientific Officer1.9yrsUS$5.65m0.076%
$ 7.4m
Jeffrey Hessekiel
Executive VP & General Counsel10.8yrsUS$4.56m0.12%
$ 11.8m
Amy Peterson
Executive VP1.3yrsUS$7.38mno data
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations7.9yrsno datano data
Tony Redmond
Senior Vice President of Human Resourcesless than a yearno datano data
Anne Champsaur
Senior Vice President of Drug Safety9.6yrsno datano data
William Berg
Senior Vice President of Medical Affairs9.2yrsno datano data
Patrick Haley
Executive Vice President of Commercial7.9yrsUS$4.65m0.049%
$ 4.8m
Stefan Krauss
VP & Head of Business Developmentno datano datano data

8.5yrs

Average Tenure

57yo

Average Age

Experienced Management: EXEL's management team is seasoned and experienced (8.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 42.3m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.55%
$ 53.2m
Jack Wyszomierski
Independent Director20.8yrsUS$490.97k0.12%
$ 11.3m
George Poste
Independent Director20.3yrsUS$482.22k0.063%
$ 6.1m
Charles Sawyers
Member of the Scientific Advisory Boardno datano datano data
Ronald Evans
Member of the Scientific Advisory Boardno datano datano data
Sue Eckhardt
Independent Directorless than a yearno data0%
$ 0
Mary Beckerle
Independent Directorless than a yearno data0%
$ 0
Julie Smith
Independent Director8.2yrsUS$490.92k0.00027%
$ 26.3k
Maria Freire
Independent Director6.6yrsUS$488.72k0.025%
$ 2.5m
Robert Oliver
Independent Director1.5yrsUS$717.44k0.0016%
$ 154.9k
Tomas Heyman
Independent Director1.5yrsUS$716.19k0.0016%
$ 154.9k

7.4yrs

Average Tenure

68yo

Average Age

Experienced Board: EXEL's board of directors are considered experienced (7.4 years average tenure).